Skip to main
AXSM

Axsome Therapeutics (AXSM) Stock Forecast & Price Target

Axsome Therapeutics (AXSM) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 47%
Buy 47%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Axsome Therapeutics Inc. is positioned for significant commercial momentum, anticipated to accelerate markedly in 2026, with a potential pathway to achieving cash flow-positive status before the midpoint of that year. The company has demonstrated strong performance with its product Auvelity, which has exceeded sales expectations, and there is a heightened probability of regulatory approval for AXS-05, now revised to 85%, following the FDA's designation of priority review. Additionally, expectations are optimistic regarding market penetration for AXS-05, reflecting the overall belief in its potential to provide meaningful advancements for patients with CNS disorders.

Bears say

Axsome Therapeutics faces significant challenges that contribute to a negative outlook on its stock, particularly regarding expected market access for its product AUVELITY, which may fall short of projections. The company is also at risk from potential setbacks in clinical trials for key products, such as AXS-05 and solriamfetol, along with delays in securing necessary approvals for additional pipeline candidates like AXS-12 and AXS-14. Furthermore, there are concerns about the competitive landscape and market penetration, which could lead to lower-than-anticipated commercial success and long-term dilution risks impacting investor sentiment.

Axsome Therapeutics (AXSM) has been analyzed by 15 analysts, with a consensus rating of Buy. 47% of analysts recommend a Strong Buy, 47% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Axsome Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Axsome Therapeutics (AXSM) Forecast

Analysts have given Axsome Therapeutics (AXSM) a Buy based on their latest research and market trends.

According to 15 analysts, Axsome Therapeutics (AXSM) has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $205, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $205, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Axsome Therapeutics (AXSM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.